From the Editor

Jan 01, 2006
Pharmaceutical Executive
Witnessing an industry's wild ride is perhaps the best reason to work for a business magazine. You've given us 25 years of excitement. And we plan to pay you back.
Dec 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The public is focused on drug safety, but the real issue isn't approval standards. It's the way drugs expand to unapproved new indications. Are you listening, Acomplia?
Nov 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Leo H. Sternbach's death feels like the end of an era, a time when the new drugs came easily and it was possible to have a huge impact on patients, then turn around and do it again.
Oct 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In an opinion piece in the September 8 New England Journal of Medicine, Harvard medical professor and long-time industry critic Jerry Avorn takes a whack at FDA, accusing the agency of practicing a level of science that wouldn’t pass muster anywhere else in research—science that’s only "good enough for government work.";
Sep 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
My doctor and I have two different visions of an avian influenza pandemic. She's picturing regular flu season, but worse. I'm imagining 1918. Does the conflict sound familiar?
Aug 01, 2005
Pharmaceutical Executive
With patients who suffer from poverty, lack of education, and disease, it is incredibly easy to do damage through a marketing tactic that might be acceptable for another group.
Jul 01, 2005
Pharmaceutical Executive
If congressmen gathered to work through the nuances of banning ED drugs from reimbursement under Medicare, they'd still back the ban. But the decision would be grounded in lack of faith in prescribing behavior, not disregard for a debilitating condition.
Jul 01, 2005
Pharmaceutical Executive
If congressmen gathered to work through the nuances of banning ED drugs from reimbursement under Medicare, they'd still back the ban. But the decision would be grounded in lack of faith in prescribing behavior, not disregard for a debilitating condition.
Jun 01, 2005
Pharmaceutical Executive
Part of the value of a drug comes from the supply chain that protects its integrity. There's a similar supply chain that preserves the value of drug information. And it needs help.
May 01, 2005
Pharmaceutical Executive
A new TV doctor show features the most loathsome pharmaceutical executive in recent memory. But in another important way, the show is serving pharma's best interests.
native1_300x100
lorem ipsum